Product
OSE-279
1 clinical trial
2 indications
Indication
Solid Advanced TumorIndication
lymphomaClinical trial
A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or LymphomasStatus: Recruiting, Estimated PCD: 2024-05-01